I don't much like this question because any response often inherently suggests one can't help with something, which may or may not be the case! I think the best answer is to give a sense of geography and some past publications demonstrating the broad spectrum of strategic challenges and project types I've experienced, and please get in touch if you would like to discuss further.

Geography: most of my work has been "Global", with various specific projects for Europe (regional or country-specific), USA, Asia-Pacific, Latin America

Access strategy & evidence for a highly innovative, personalized cell therapy in a rare, multi-disease indication

Irwin J et al. Posters presented at ISPOR Europe, Nov 2019:

https://doi.org/10.1016/j.jval.2019.09.1763

https://doi.org/10.1016/j.jval.2019.09.1626

Leadership from conceptualisation to publication for various real-world evidence generation studies

Patient preference in ITP (TRAPeze): McDonald V et al. Hematology. 2021 Dec;26(1):799-808. doi: 10.1080/16078454.2021.1978689

BoD in Parkinson's (PRISM): Webb, J et al. [abstract]. In: 5th World Parkinson Congress; 2019 4-7th June; Kyoto, Japan. Abstract P43.02: https://content.iospress.com/download/journal-of-parkinsons-disease/jpd199900?id=journal-of-parkinsons-disease%2Fjpd199900

BoD in Dravet: Strzelczyk A et al. Epilepsia 2019; https://onlinelibrary.wiley.com/doi/full/10.1111/epi.16099

Various protocol-led Delphi panels in multiple disease areas (haemato-oncology, CVD)

Market shaping & access challenges

BoD in lung cancer: Johal S et al. J Thoracic Dis 2021;13(6): https://jtd.amegroups.com/article/view/51573/html

Cost drivers with PARPis in cancer: McCrea C et al. Poster presented at ISPOR Europe, Nov 2019: https://doi.org/10.1016/j.jval.2019.09.403